Sten Myrehaug

Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial

Arjun Sahgal, Sten Myrehaug, Shankar Siva et al. · The Lancet Oncology · 2021 · 404 citations

Medicine, Oncology, Radiation Oncology +15

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Simron Singh, Daniel Halperin, Sten Myrehaug et al. · The Lancet · 2024 · 324 citations · Full text

Medicine, Oncology, Pharmacology +17

MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases

Ying Meng, Raymond M. Reilly, Rossanna C. Pezo et al. · Science Translational Medicine · 2021 · 220 citations

Medicine, Oncology, Pharmaceutics +17

A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma

Andra Krauze, Sten Myrehaug, Michael G. Chang et al. · International Journal of Radiation Oncology*Biology*Physics · 2015 · 203 citations

Medicine, Oncology, Radiation Oncology +16

Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy

Sten Myrehaug, Melania Pintilie, Richard Tsang et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2008 · 170 citations

Medicine, Cardiology, Oncology +17